Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXPAREL vs bupivacaine in pediatric cardiac surgery
NCT06271265Phase 1Recruiting
- Sponsor
- Pacira BioSciences
- Start
- Mar 2024
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of liposomal bupivacaine in postoperative pain (2 arms), sponsored by Pacira BioSciences. Primary endpoints: Area Under the Concentration-Time Curve at 72 hours, Maximum Plasma Concentration at 72 hours and 4 more. Started Mar 2024; status: recruiting.
02
Drugs
liposomal bupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NCT06271265.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06271265.